GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
| Mar2021 | ₹2,804 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | -54.72 | |
| Mar2021 | ₹2,804 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹55,614.6 Cr | -1% | -3.7% | 32.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹391,488.0 Cr | -2.5% | -7% | -8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,415.0 Cr | -2.2% | -7.2% | 1.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹132,906.0 Cr | -4% | 2.8% | 27.1% | Stock Analytics | |
| CIPLA | ₹106,210.0 Cr | -5.5% | -12.4% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,089.0 Cr | 5.9% | -3.7% | -6.5% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -1% |
-3.7% |
32.7% |
| SENSEX | -2.4% |
-4.7% |
6.4% |
You may also like the below Video Courses